Optimal initial anticoagulant therapy in pulmonary thromboembolism: randomized trial suggested
Numerous lines of evidence suggest a need for an improvement in pulmonary thromboembolism (PTE) therapy: According to relevant US data (Heart Disease and Stroke Statistics–2012 Update), 30-day mortality of PTE is no less than 40.9%, which is clearly not acceptable .
Source: The American Journal of Emergency Medicine - Category: Emergency Medicine Authors: Goran P. Koracevic Tags: Correspondence Source Type: research
More News: Cardiology | Emergency Medicine | Heart | Heart Disease | Pulmonary Thromboembolism | Statistics | Stroke | Thrombosis